Baird Medical Announces First Successful Liver Tumor Ablation in Bangladesh

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced the company’s first successful microwave ablation (MWA) liver tumor procedure in Bangladesh on Oct 23, 2025. The treatment was performed at USB Hospital in Uttara, Dhaka, by Dr. Mofazzal Sharif Rasel and team on a 65-year-old patient with a 6 cm liver tumor, who is reported to be recovering well. The event represents a commercial and clinical adoption milestone for Baird Medical in South Asia and underscores the company’s stated focus on expanding global access to minimally invasive tumor therapies through strategic clinician and institution partnerships.

Positive

• First commercial MWA procedure completed in Bangladesh
• Treated a 6 cm liver tumor successfully
• Procedure led by a local specialist, supporting clinical adoption in South Asia
• Patient reported to be recovering well, supporting safety signal

Negative

• None.

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of its first MWA procedure in Bangladesh. The landmark treatment was performed at USB Hospital in Uttara, Dhaka, marking a significant step forward in the availability of cutting-edge, non-surgical cancer therapies in the region.

The procedure was led by Dr. Mofazzal Sharif Rasel, a distinguished interventional radiologist, and his expert medical team. The patient, a 65-year-old individual diagnosed with a challenging 6 cm liver tumor, underwent the minimally invasive MWA procedure successfully and is reported to be recovering exceptionally well.

"This first procedure in Bangladesh represents a profoundly important milestone for our team," said Haimei Wu, Chairwoman of Baird Medical. "It demonstrates the growing global confidence in our MWA technology and, more importantly, signifies a new era of access to advanced, minimally invasive treatment options for patients in South Asia."

Baird Medical remains committed to strengthening its global presence through strategic collaborations with leading clinicians and medical institutions, broadening access to innovative, minimally invasive tumor treatment solutions worldwide.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-announces-first-successful-liver-tumor-ablation-in-bangladesh-302592450.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce on October 23, 2025 about Bangladesh?

Baird Medical announced its first successful microwave ablation (MWA) liver tumor procedure performed at USB Hospital in Dhaka.

Where in Bangladesh was BDMD's first MWA liver procedure performed?

The procedure was performed at USB Hospital in Uttara, Dhaka.

Who led the BDMD procedure in Bangladesh and what was the patient case?

Dr. Mofazzal Sharif Rasel led the team treating a 65-year-old patient with a 6 cm liver tumor.

Does the BDMD announcement indicate patient outcome after the Bangladesh procedure?

Yes, the company reported the patient is recovering well following the minimally invasive MWA procedure.

What does BDMD say this Bangladesh milestone means for the company?

Baird Medical said the milestone demonstrates growing global confidence in its MWA technology and expands access to minimally invasive tumor treatments in South Asia.